Read More

Gain Therapeutics Highlights Presentation Of Preclinical Data Demonstrating Potential Disease Modifying Benefits Of Its Novel Brain Penetrant Small Molecule Candidate GT-02287 In Two Preclinical Models Of Parkinson’s Disease

Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills   Results Presented at the International Congress of Parkinson's Disease and

GANX

Read More

Heron Therapeutics Announces U.S. FDA Approval Of APONVIE For The Prevention Of Postoperative Nausea And Vomiting

  - APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for PONV - - Delivered via a single 30-second IV injection, APONVIE has demonstrated rapid achievement of therapeutic drug levels ideally suited for the surgical setting -

HRTX